
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is well-positioned in the rapidly growing field of precision oncology and has a strong pipeline of precision therapies, including a promising candidate for non-CNS cancers such as pancreatic and lung cancer, as well as a next-generation brain-penetrant PRMT5 inhibitor for CNS cancers. The company's recent financial results and updated development assumptions for its lead asset, vopimetostat, support a discounted cash flow-based valuation of $11.6B, with a 12-month price objective of $68 per share. Upcoming catalysts, including data presentations and ongoing clinical trials, provide further potential for company growth. Risks to achieving the price target include negative clinical results, delays in pipeline progress, and potential competitive pressures.
Bears say
Tango Therapeutics is heavily focused on discovering and developing precision oncology therapies, specifically targeting KRAS and PRMT5. However, the market is highly competitive, with multiple players already in the market or poised to enter. Additionally, its success hinges on the success of its combination therapies with Revolution Medicines' daraxonrasib and zoldonrasib. If these combinations do not demonstrate efficacy or encounter safety issues, it could result in downside risk to the stock and its price target. There is also the potential for delays in FDA approval for vopimetostat, and any delays or issues could also negatively impact the stock.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares